论文部分内容阅读
目的评价重组甘精胰岛素联合阿卡波糖对老年2型糖尿病患者的疗效和安全性。方法 50例老年T2DM患者分为重组甘精胰岛素联合阿卡波糖(A组)和预混胰岛素(B组)进行治疗,观察治疗前后FBG、2hBG、HbA1c、BMI、血糖波动幅度(MAGE)、低血糖的频率及程度等情况。结果治疗后两组FBG、2hBG、HbA1c下降(P<0.05),A组低血糖发生率、程度及MAGE均低于B组(P<0.05),A组体重下降0.5kg,B组体重增加1.2kg,差异无统计学意义(P>0.05)。结论重组甘精胰岛素联合阿卡波糖可有效降低老年T2DM患者血糖,且低血糖发生率低,安全性高。
Objective To evaluate the efficacy and safety of recombinant glargine plus acarbose on elderly type 2 diabetic patients. Methods Fifty elderly patients with T2DM were divided into two groups: group A, group A and group B, group B, FBG, HbA1c, BMI, MAGE, The frequency and degree of hypoglycemia and so on. Results After treatment, FBG, 2hBG and HbA1c in two groups decreased (P <0.05). The incidence of hypoglycemia and MAGE in group A were lower than those in group B (P <0.05). The body weight of group A dropped 0.5kg and the weight of group B increased 1.2 kg, the difference was not statistically significant (P> 0.05). Conclusion Recombinant insulin glargine combined with acarbose can effectively reduce the blood sugar in elderly patients with T2DM, and the incidence of hypoglycemia is low and safe.